Scientific Institute for Advanced Nutrition
Advancing the science and clinical translation of BHB in metabolic nutrition
The Scientific Institute for Advanced Nutrition is an independent scientific body dedicated to advancing evidence-based metabolic nutrition through rigorous science, expert dialogue, and clinically relevant translation. Building on the momentum of its inaugural special focus meeting, SIAN now brings forward an ongoing programme of scientific collaboration, faculty leadership, and focused work on the role of BHB in applied metabolic nutrition.
- 01
Independent scientific institute
- 02
International faculty across Europe, Japan, and the United States
- 03
Inaugural BHB special focus meeting completed in June 2026
What SIAN exists to do
SIAN was established to provide an independent forum for advancing the science, standards, and clinical relevance of metabolic nutrition. Its purpose is to bring together leading experts across medicine, nutritional science, regulation, and innovation to define the evidence required for responsible progress in BHB and related advanced nutrition applications.
The institute places particular emphasis on high-quality, indication-specific clinical data, robust scientific and manufacturing standards, and clear translational pathways that allow clinicians, researchers, and regulators to engage with the field confidently. SIAN’s work is grounded in scientific rigour, transparency, and the belief that advanced nutrition products must be supported by both credible evidence and reliable supply if they are to be used with confidence in practice.
Science
Generating and evaluating high-quality, indication-specific evidence for metabolic nutrition.
Standards
Defining robust scientific and manufacturing standards for responsible field development.
Clinical translation
Building clear pathways from mechanism to clinically relevant application.
Independent convening
Bringing experts together across medicine, science, regulation, and innovation.
What emerged from the first SIAN meeting
SIAN’s inaugural special focus meeting brought together leading international speakers to examine the present and future role of beta-hydroxybutyrate in applied metabolic nutrition. Across keynote lectures, specialist sessions, and faculty discussion, the meeting explored the evidence base for BHB, its emerging clinical and functional applications, and the scientific, regulatory, and supply questions that must be addressed to move the field forward responsibly.
A clear message emerged from the meeting: BHB is now being considered not simply as an alternative fuel, but as a molecule of growing interest across multiple areas of metabolic and neurological relevance. At the same time, the discussions underscored that future progress will depend on stronger indication-specific evidence, clearer standards, and closer alignment between scientific discovery, real-world application, and product quality.
The programme highlighted key areas of current interest. Rather than concluding a conversation, the first meeting established a foundation for ongoing scientific collaboration and future SIAN work.
Review the full inaugural meeting programmeAreas of current interest
- Neuroprotection
- Migraine
- Diabetes-related hypoglycaemia
- Cognition
- Performance
- Epilepsy
- Mitochondrial health
- Production innovation
- Regulatory landscape
- Polycystic kidney disease
01BHB is moving into a more structured phase of scientific and translational development.
02The next stage of progress will require better evidence, more consistent standards, and a regulatory infrastructure that supports responsible innovation — without creating unnecessary barriers to consumer access.
03Meaningful advancement will depend on collaboration across clinical science, metabolic research, regulation, and manufacturing quality.
A faculty spanning Europe, Japan, and the United States
SIAN’s work is guided by an international faculty of clinical investigators, metabolic scientists, regulatory experts, and production innovators — bringing deep, indication-specific expertise to the science of BHB and applied metabolic nutrition.
Prof. Dominic D'Agostino
Neuroprotection and metabolic therapies
Dr. Mary Newport
Brain energy metabolism and neuroprotection
Dr. Elena Gross
Migraine and metabolic neuroscience
Prof. Dr. Ben Bikman
Mitochondrial health and metabolic function
Prof. Dr. Christina Heidt
Clinical nutrition and rare metabolic disorders
Dr. Jacob Wilson
Body composition and performance
Dr. Ryley Parrish
Epilepsy and brain excitability
Prof. Dr. D. Russell-Jones
Diabetes and clinical evidence
Dr. Jun Tsubota
BHB production and precision fermentation
Mr. Satoshi Morita
Cognition and mental performance
Dr. Richard Littlewood
Clinical translation and regulation
Prof. Thomas Weimbs
Polycystic kidney disease and metabolic signalling
Prof. J. Walsh
Exercise, exogenous ketones, and long-term brain health
Carrying the discussion into structured work
Following the first meeting, SIAN is developing a Special Working Group on BHB to carry the discussion forward into a more structured programme of activity. The aim of the group is to connect scientific insight with practical next steps by aligning experts around evidence priorities, translational opportunities, supply and production considerations, and the standards needed for responsible field development.
- 01
Clinical evidence and prioritisation
Identifying the indication-specific studies and evidence standards needed to advance the field responsibly.
- 02
Applications and translation
Connecting mechanism and discovery to clinically and functionally relevant applications.
- 03
Supply, quality, and manufacturing
Addressing reliable supply and consistent product quality as prerequisites for confident use.
- 04
Regulation and standards
Aligning on the regulatory frameworks and standards required for credible, responsible progress.
SIAN Meeting 2
South Florida · 8–9 December 2026
SIAN’s next convening is planned for South Florida on 8–9 December 2026 and will build directly on the momentum of the inaugural meeting. The programme is expected to bring together keynote leaders in BHB science alongside parallel workstreams focused on therapeutic and applied use cases, supply and manufacturing quality, and the evidence and regulatory frameworks needed for credible progress.
Stay connected with SIAN
Register your interest to receive updates on the December 2026 meeting, future institute activities, faculty announcements, and developments from the Special Working Group on BHB.